Recruiting

Quest AD-Detect

Sponsor:

Covenant Health, US

Code:

NCT07222280

Conditions

Alzheimer Dementia

Alzheimer Disease

Delirium Confusional State

Encephalopathy

Cognitive Abnormality

Eligibility Criteria

Sex: All

Age: 60 - 70+

Healthy Volunteers: Not accepted

Interventions

Quest AD-Detect blood test

Study Details

Brief summary:

The goal of this clinical trial is to determine if utilizing the Quest AD-Detect blood test, while patient's are hospitalized for a cognitive diagnosis (such as delirium or encephalopathy), will result in an earlier diagnosis of underlying Alzheimer's disease.

  • Will this blood test have the ability to distinguish between Alzheimer's disease and other causes of cognitive impairment in the inpatient setting?
  • Neurology Clinic will complete a 6-month post-hospitalization follow up with patients who have had the Quest AD-Detect Alzheimer's Disease blood test completed while they were inpatient to discuss the risk assessment portfolio

Conditions

Alzheimer Dementia

Alzheimer Disease

Delirium Confusional State

Encephalopathy

Cognitive Abnormality

Study ID

NCT07222280

Start date

Jun 10, 2025

Status verified date

Oct, 2025

Completion date

Mar 31, 2026

Anticipated

Primary completion date

Mar 31, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 60 - 70+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Ages 60 to 90 years old
  • No prior diagnosis of dementia
  • Currently hospitalized with cognitive diagnosis, including but no limited to; delirium, encephalopathy, etc. thought to be secondary to a toxic/metabolic state

Exclusion Criteria:

  • Age under 60 years
  • Prior diagnosis of dementing illness or other organic etiology to cognitive impairment

Study Design

Enrollment

30 participants

Anticipated

Intervention Model

Single group

Primary purpose

Diagnostic

Interventions and Outcome Measures

Arms

other: All eligible patients will receive a Quest AD-Detect blood test

All patients that meet the inclusion criteria, and none of the exclusion criteria, will have their blood tested with the Quest AD-Detect

Interventions

Quest AD-Detect blood test

Blood will be collected and sent for testing using the Quest AD-Detect blood test

Primary outcome measure

  • To show the percentage of patients (21 patients in the study) who presented with a cognitive diagnosis (including but not limited to delirium, encephalopathy, etc.) that have a positive biomarker for Alzheimer's dementia [ Time Frame: From enrollment to 6 month follow up appointment with Neurology Clinic. ]

Central Contacts and Locations

Central contacts

Clinical Research Nurse Coordinator

865-331-1337aholt10@covhlth.com

Locations

Cumberland Medical Center

Recruiting

Crossville, Tennessee, United States, 38555

Contacts

Clinical Research Nurse Coordinator

865-331-1337aholt10@covhlth.com

Principal Investigator:

Samuel A. Moore, MD

Roane Medical Center

Recruiting

Harriman, Tennessee, United States, 37748

Contacts

Clinical Research Nurse Coordinator

865-331-1337aholt10@covhlth.com

Principal Investigator:

Samuel A. Moore, MD

Fort Sanders Regional Medical Center

Recruiting

Knoxville, Tennessee, United States, 37916

Contacts

Clinical Research Nurse Coordinator

865-331-1337aholt10@covhlth.com

Principal Investigator:

Samuel A. Moore, MD

Fort Loudon Medical Center

Recruiting

Lenoir City, Tennessee, United States, 37772

Contacts

Clinical Research Nurse Coordinator

865-331-1337aholt10@covhlth.com

Principal Investigator:

Samuel A. Moore, MD

Methodist Medical Center

Recruiting

Oak Ridge, Tennessee, United States, 37830

Contacts

Clinical Research Nurse Coordinator

865-331-1337aholt10@covhlth.com

Principal Investigator:

Samuel A. Moore, MD

LeConte Medical Center

Recruiting

Sevierville, Tennessee, United States, 37862

Contacts

Clinical Research Nurse Coordinator

865-331-1337aholt10@covhlth.com

Principal Investigator:

Samuel A. Moore, MD

More Information

Sponsor

Covenant Health, US

Last update posted

Oct 29, 2025

Last verified

Oct, 2025

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Covenant Health, US on 2025-10-29.